Your browser is no longer supported. Please, upgrade your browser.
IMVT Immunovant, Inc. daily Stock Chart
Immunovant, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own64.90% Shs Outstand70.82M Perf Week-0.59%
Market Cap3.64B Forward P/E- EPS next Y-1.70 Insider Trans0.69% Shs Float27.90M Perf Month21.67%
Income-58.40M PEG- EPS next Q-0.34 Inst Own32.60% Short Float8.50% Perf Quarter71.14%
Sales- P/S- EPS this Y7.10% Inst Trans0.66% Short Ratio4.69 Perf Half Y129.06%
Book/sh3.78 P/B11.16 EPS next Y-18.90% ROA-36.30% Target Price47.60 Perf Year315.88%
Cash/sh3.25 P/C12.97 EPS next 5Y- ROE-39.80% 52W Range8.34 - 43.94 Perf YTD165.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-4.03% Beta-
Dividend %- Quick Ratio14.60 Sales past 5Y- Gross Margin- 52W Low405.64% ATR2.39
Employees51 Current Ratio14.60 Sales Q/Q- Oper. Margin- RSI (14)60.06 Volatility5.83% 5.93%
OptionableNo Debt/Eq0.00 EPS Q/Q56.10% Profit Margin- Rel Volume0.48 Prev Close41.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume506.38K Price42.17
Recom1.60 SMA206.86% SMA5015.60% SMA20076.60% Volume242,750 Change1.27%
Oct-12-20Initiated Guggenheim Buy $63
Oct-08-20Initiated Stifel Buy $46
Oct-02-20Initiated Credit Suisse Outperform $49
Aug-26-20Reiterated H.C. Wainwright Buy $34 → $40
Aug-25-20Initiated Raymond James Outperform $35
Jul-29-20Initiated H.C. Wainwright Buy $34
Feb-24-20Initiated SVB Leerink Outperform $24
Oct-20-20 10:25AM  
Oct-14-20 06:19PM  
Oct-06-20 04:24PM  
Sep-15-20 12:43AM  
Sep-07-20 03:30PM  
Sep-04-20 04:01PM  
Sep-02-20 04:15PM  
Aug-25-20 04:15PM  
Aug-24-20 08:00AM  
Aug-13-20 12:59PM  
Aug-12-20 04:01PM  
Jul-12-20 01:34PM  
Jun-29-20 07:30AM  
Jun-08-20 02:09AM  
May-14-20 07:30AM  
Apr-16-20 04:01PM  
Apr-14-20 09:28AM  
Mar-30-20 07:30AM  
Mar-10-20 08:05AM  
Mar-03-20 08:00AM  
Feb-14-20 07:00AM  
Feb-10-20 07:00AM  
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butchko Julia G.Chief Dev. & Tech. OfficerSep 11Buy38.175,000190,8505,000Sep 15 05:09 PM
Roivant Sciences Ltd.10% OwnerSep 04Buy33.00380,00012,540,00047,593,419Sep 04 05:29 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.